Literature DB >> 20035782

Post-weaning social isolation increases activity in a novel environment but decreases defensive burying and subchronic MK-801 enhances the activity but not the burying effect in rats.

Sarah M Simpson1, Janet L Menard, James N Reynolds, Richard J Beninger.   

Abstract

Subchronic treatment with a non-competitive glutamate NMDA-receptor antagonist [e.g., MK-801 or phencyclidine] or social isolation (SI) from weaning (age 21 days) to adulthood (age 56 days) produce deficits similar to some of the positive and negative symptoms of schizophrenia. Few studies have evaluated the effects of these treatments on emotional behavior. We hypothesized that subchronic MK-801, post-weaning SI or the two in combination would alter activity in a novel environment, anxiety-like behaviors in the elevated plus-maze, coping responses in the defensive burying paradigm and social behavior. In experiment 1, SI rats (n=17) showed increased locomotor activity when exposed to a novel environment, no change in plus-maze behavior and decreased defensive burying when compared to group housed rats (n=16). Subchronic MK-801 enhanced the increase in activity but not the decrease in burying in SI rats. Experiment 2 evaluated the effects on social behavior of post-weaning SI. The locomotor and burying results of experiment 1 were replicated and SI rats (n=9) were found to decrease orientation towards a novel conspecific social target when compared to group housed rats (n=8). The behavioral abnormalities of SI rats may be a manifestation of GABAergic dysfunction that has recently become evident in schizophrenia. (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20035782     DOI: 10.1016/j.pbb.2009.12.008

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  7 in total

Review 1.  Obsessive-compulsive disorder: Insights from animal models.

Authors:  Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter
Journal:  Neurosci Biobehav Rev       Date:  2016-05-07       Impact factor: 8.989

2.  Prolonged exposure to NMDAR antagonist induces cell-type specific changes of glutamatergic receptors in rat prefrontal cortex.

Authors:  Huai-Xing Wang; Wen-Jun Gao
Journal:  Neuropharmacology       Date:  2011-12-09       Impact factor: 5.250

3.  The effects of N-Methyl-D-Aspartate receptor blockade during the early neurodevelopmental period on emotional behaviors and cognitive functions of adolescent Wistar rats.

Authors:  Sayad Kocahan; Kubra Akillioglu; Secil Binokay; Leman Sencar; Sait Polat
Journal:  Neurochem Res       Date:  2013-03-06       Impact factor: 3.996

4.  Sansoninto attenuates aggressive behavior and increases levels of homovanillic acid, a dopamine metabolite, in social isolation-reared mice.

Authors:  Takuya Watanabe; Hikari Iba; Hiroshi Moriyama; Kaori Kubota; Shutaro Katsurabayashi; Katsunori Iwasaki
Journal:  J Tradit Complement Med       Date:  2021-08-10

5.  Increased drinking following social isolation rearing: implications for polydipsia associated with schizophrenia.

Authors:  Emily R Hawken; Nicholas J Delva; Richard J Beninger
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

6.  Down-Regulation of Hippocampal Genes Regulating Dopaminergic, GABAergic, and Glutamatergic Function Following Combined Neonatal Phencyclidine and Post-Weaning Social Isolation of Rats as a Neurodevelopmental Model for Schizophrenia.

Authors:  Philip Lr Gaskin; Maria Toledo-Rodriguez; Stephen Ph Alexander; Kevin Cf Fone
Journal:  Int J Neuropsychopharmacol       Date:  2016-12-03       Impact factor: 5.176

7.  Olanzapine Reverses MK-801-Induced Cognitive Deficits and Region-Specific Alterations of NMDA Receptor Subunits.

Authors:  Xiao Liu; Jitao Li; Chunmei Guo; Hongli Wang; Yaxin Sun; Han Wang; Yun-Ai Su; Keqing Li; Tianmei Si
Journal:  Front Behav Neurosci       Date:  2018-01-09       Impact factor: 3.558

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.